CommercialPrior AuthMedium impact
Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Hematology·Pharmacy
We identified it
Jun 20, 2026
Summary
Blue Cross Blue Shield of Mississippi updated their policy for donor lymphocyte infusion (DLI) following stem cell transplants for blood cancers. The policy confirms DLI is medically necessary for relapsed/refractory hematologic malignancies after allogeneic transplant, but requires prior authorization through case management.
Action Required
Immediately: Ensure all donor lymphocyte infusion procedures (CPT 38242) for hematologic malignancy patients require prior authorization through BCBS Mississippi case management before scheduling. Update billing system to flag these cases. Claims will be denied without proper prior authorization.